RESOLUTE Global: 5 Years of Zotarolimus DES Stenting

5 Years of ZotarolimusDES StentingThis study assessed the cumulative incidence of cardiovascular evens after zotarolimus eluting stent implantation.

 

Individual studies often lack enough statistical power to show differences in low frequency adverse events. The Resolute zotarolimus eluting stent was evaluated across 10 prospective clinical trials designed with identical adverse events definitions.

 

The Global Resolute clinical trial program included a total of 7,618 patients, from the Resolute first-in-human (n=139) to the Resolute International (n=2349); all 10 studies were carried out in the US, China or Japan, specifically.

 

The cumulative incidence of cardiac events at 5 years was 13.4% for target vessel failure, which included 5% of cardiac death, 4.4% of target vessel acute myocardial infarction and 6.3% ischemia driven target vessel revascularization.

 

Dual antiaggregation therapy rate at 1. 3 and 5 years was 91%, 37% and 32% respectively.

 

The cumulative incidence of probable or definite thrombosis at 5 years was 1.2%, which included 0.7% of thrombosis the first year and an annualized risk of 0.1% per year as from the second year and up to the fifth.

 

The use of dual antiaggregation at 5 years varied geographically; it reached 63% in Japan and only 11% in Europe.

 

Conclusion

This the largest study of patients receiving the zotarolimus eluting stent so far. Most of events associated to this device, including target vessel myocardial infarction and stent thrombosis, occurred the first year and risk decreased significantly as time went by.

 

Original Title: 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.

Reference: Yeh RW et al. JACC CardiovascInterv. 2017 Feb 13;10(3):247-254.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...